Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
130M
-
Number of holders
-
291
-
Total 13F shares, excl. options
-
147M
-
Shares change
-
-492K
-
Total reported value, excl. options
-
$4.79B
-
Value change
-
-$48.2M
-
Put/Call ratio
-
0.72
-
Number of buys
-
180
-
Number of sells
-
-147
-
Price
-
$32.51
Significant Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) as of Q2 2025
386 filings reported holding PCVX - Vaxcyte, Inc. - COMMON STOCK as of Q2 2025.
Vaxcyte, Inc. - COMMON STOCK (PCVX) has 291 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 147M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (14.7M shares), FMR LLC (12.2M shares), VANGUARD GROUP INC (12M shares), RA CAPITAL MANAGEMENT, L.P. (12M shares), BlackRock, Inc. (10.6M shares), T. Rowe Price Investment Management, Inc. (6M shares), WELLINGTON MANAGEMENT GROUP LLP (4.95M shares), STATE STREET CORP (4.94M shares), Capital Research Global Investors (4.77M shares), and Paradigm Biocapital Advisors LP (3.37M shares).
This table shows the top 291 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.